{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:17:48Z","timestamp":1791263868973,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2015,12,15]]},"DOI":"10.1093\/cid\/civ677","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T03:14:31Z","timestamp":1439435671000},"page":"1825-1830","source":"Crossref","is-referenced-by-count":48,"title":["Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy"],"prefix":"10.1093","volume":"61","author":[{"given":"Stacey B.","family":"Trooskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay R.","family":"Kostman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,12]]},"reference":[{"key":"2015112503522323000_61.12.1825.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"2015112503522323000_61.12.1825.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8897"},{"key":"2015112503522323000_61.12.1825.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7735"},{"key":"2015112503522323000_61.12.1825.4","unstructured":"Spach DH , Kim HN . Hepatitis C online: medications to treat HCV. Seattle: University of Washington, 2014. Available at: http:\/\/www.hepatitisc.uw.edu\/page\/treatment\/drugs . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(14)61225-3","article-title":"Hepatitis C beware\u2014 the end is nigh","volume":"384","author":"Gane","year":"2014","journal-title":"Lancet"},{"key":"2015112503522323000_61.12.1825.6","doi-asserted-by":"publisher","DOI":"10.1038\/508295a"},{"key":"2015112503522323000_61.12.1825.7","article-title":"How Illinois allocates $84,000 drug for hepatitis C: treatment's high cost required stringent criteria, official says","author":"Silverman","year":"2014","journal-title":"Wall Street Journal"},{"key":"2015112503522323000_61.12.1825.8","unstructured":"US Senate Committee on Veterans Affairs [audiovisual recording]. Senate panel probes exorbitant prices for hepatitis C drugs [hearing]. Washington, DC, 2014. Available at: http:\/\/www.veterans.senate.gov\/hearinghepatitis-c-in-veterans . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.9","first-page":"1","article-title":"Limited access to new hepatitis C virus treatment under state Medicaid programs","author":"Canary","year":"2015","journal-title":"Ann Intern Med"},{"key":"2015112503522323000_61.12.1825.10","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0406"},{"key":"2015112503522323000_61.12.1825.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26218"},{"key":"2015112503522323000_61.12.1825.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02494.x"},{"key":"2015112503522323000_61.12.1825.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.07.015"},{"key":"2015112503522323000_61.12.1825.14","article-title":"Drug pricing: bitter pill, a hepatitis treatment's soaring price is prompting the debate that most alarms the industry","author":"Ward","year":"2014","journal-title":"Financial Times"},{"key":"2015112503522323000_61.12.1825.15","unstructured":"Gilead Sciences, Inc. Gilead Sciences announces fourth quarter and full year 2014 financial results. Foster City, CA: Gilead, 2015. Available at: http:\/\/investors.gilead.com\/phoenix.zhtmI?c=69964&p=irol-earnings . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.16","unstructured":"National Center for Health Statistics (US). Health, United States, 2013: with special feature on prescription drugs. Report No. 2014-1232. Hyattsville, MD: National Center for Health Statistics, 2014. Available at: http:\/\/www.ncbi.nlm.nih.gov\/bookNBK209224\/ . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.17","unstructured":"Edlin BR , Graham C , Gish R . Position paper to: US Health and Human Services Secretary Sylvia Burwell re: hepatitis C treatment barriers. San Francisco, CA: National Viral Hepatitis Roundtable, 2014. Available at: http:\/\/nvhrorg\/sites\/default\/files\/docs\/Secretary%20Burwell%2009_10_14.pdf . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.18","unstructured":"Gordon D , Betlach T . Letter to: US Congressional representatives re: HCV pricing. Washington, DC: National Association of Medicaid Directors, 2014. Available at: http:\/\/medicaiddirectors.org\/sites\/medicaiddirixtors.org\/files\/public\/namd_sovaldiletterto_congress_10-28-14.pdf . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu012"},{"key":"2015112503522323000_61.12.1825.20","unstructured":"Missouri Department of Social Services. Missouri, as part of 25-state consortium, designates new hepatitis C drug for Medicaid patients; reaches agreement that will save taxpayers millions of dollars in fiscal year 2016. Jefferson City, MO: Department of Social Services, 2015. Available at: http:\/\/dss.mo.gov\/press\/150126-missouri-designates-new-hepatitis-c-drug-formedicaid-patients.htm . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.21","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/474S18a","article-title":"Perspective: test and treat this silent killer","volume":"474","author":"Edlin","year":"2011","journal-title":"Nature"},{"key":"2015112503522323000_61.12.1825.22","unstructured":"Centers for Disease Control and Prevention. Hepatitis C information for health professionals. Available at: http:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.23","unstructured":"Kardish C . The risky business of limiting Medicaid access to Sovaldi. Tribune Regional News, 2015. Available at: http:\/\/www.governing.com\/topics\/health-human-services\/gov-hepatitis-coverage-solvaldi-lawsuits.html . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1311941"},{"key":"2015112503522323000_61.12.1825.25","unstructured":"Leof A , Gerrity M , Thielke A , King V . Sofosbuvir for the treatment of hepatitis C and evaluation of the 2014 American Association for the Study of Liver Diseases treatment guidelines. Portland, OR: Center for Evidence-Based Policy, Oregon Health & Science University, 2014. Available at: http:\/\/www.ohsu.edu\/xd\/research\/centers-institutes\/evidence-based-policycenter\/med\/upload\/Sofosbuvir_for_HepatitisC_FINALDRAFT_6_12_2014.pdf . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.26","article-title":"OTP patients, ideal for new hepatitis C medication, put on bottom of list by payers","author":"Knopf","year":"2015","journal-title":"Alcohol Drug Abuse Wkly"},{"key":"2015112503522323000_61.12.1825.27","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.25.w262"},{"key":"2015112503522323000_61.12.1825.28","unstructured":"American Association for the Study of Liver Diseases. AASLD position on treating patients with chronic hepatitis C virus, 2014. Available at: http:\/\/www.aasld.org\/aasld-position-treating-patients-chronic-hcv . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.29","unstructured":"American Association for the Study of Liver Diseases\/Infectious Diseases Society of America\/International AIDS Society\u2013USA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C, 2014. Available at: http:\/\/www.hcvguidelines.org . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.30","unstructured":"Gilead Sciences, Inc. Gilead Sciences policy position: Gilead's efforts to ensure patient access to Sovaldi for chronic hepatitis C. Foster City, CA: Gilead, 2014. Available at: http:\/\/www.gilead.com\/approximately\/media\/Files\/pdfs\/Policy-Perspectives\/Patient-Access-to-SOF-for-HCV-4-28-14.pdf . Accessed 10 March 2015."},{"issue":"7 suppl","key":"2015112503522323000_61.12.1825.31","first-page":"5","article-title":"Common methodological flaws in economic evaluations","volume":"43","author":"Drummond","year":"2005","journal-title":"Med Care"},{"key":"2015112503522323000_61.12.1825.32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2055-6640(20)30491-X","article-title":"HCV cure for everyone or which challenges remain?","volume":"1","author":"Rockstroh","year":"2015","journal-title":"J Virus Erad"},{"key":"2015112503522323000_61.12.1825.33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit301"},{"key":"2015112503522323000_61.12.1825.34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27010"},{"key":"2015112503522323000_61.12.1825.35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/jvh.12311","article-title":"Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C","volume":"22","author":"Leleu","year":"2014","journal-title":"J Viral Hepat"},{"key":"2015112503522323000_61.12.1825.36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-55"},{"key":"2015112503522323000_61.12.1825.37","article-title":"India rejects Gilead's hepatitis C drug patent request","author":"Chatterjee","year":"2015","journal-title":"Reuters"},{"key":"2015112503522323000_61.12.1825.38","article-title":"The cost of a cure: Medicare's role in treating hepatitis C","author":"Neuman"},{"key":"2015112503522323000_61.12.1825.39","article-title":"Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival","author":"Humer","year":"2014","journal-title":"Reuters"},{"key":"2015112503522323000_61.12.1825.40","article-title":"States work to strike deals for hep C drug discounts: AbbVie and Gilead fight for market share in Medicaid programs","author":"Loftus","year":"2015","journal-title":"Wall Street Journal"},{"key":"2015112503522323000_61.12.1825.41","unstructured":"Center for Responsive Politics. Influence and lobbying: pharmaceuticals\/health products. Washington, DC : Center for Responsive Politics, 2015. Available at: http:\/\/www.opensecrets.org\/industries\/lobbying.php?cycle=2014&ind=H04 . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.42","unstructured":"Love J . Non-voluntary use of patents for drugs to treat the hepatitis C virus in the United States: mechanisms available to the federal government, state governments and private actors [policy brief]. Washington, DC: Knowledge Ecology International, 2014. Available at: http:\/\/keionline.org\/sites\/default\/files\/Non-voluntary_use_HCVpatents_USA.pdf . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.43","unstructured":"US Department of Health and Human Services. HHS, Bayer agree to Cipro purchase, 2001. Available at: http:\/\/archive.hhs.gov\/news\/press\/2001pres\/20011024.html . Accessed 10 March 2015."},{"key":"2015112503522323000_61.12.1825.44","unstructured":"Sanders B . Letter to Hon. Robert A. McDonald, Secretary, US Department of Veterans Affairs re: Hepatitis C drug patents, 2015. Available at: http:\/\/www.sanders.senate.gov\/download\/051215-letter\/?inline=file . Accessed 25 July 2015."}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/12\/1825\/965295\/civ677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T04:31:09Z","timestamp":1599453069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,12]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,11,24]]},"published-print":{"date-parts":[[2015,12,15]]}},"alternative-id":["10.1093\/cid\/civ677"],"URL":"https:\/\/doi.org\/10.1093\/cid\/civ677","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,12]]}}}